肿瘤多药耐药 z-bo 2020-09-19 331

　　Professor Liang Gaolin's group from the School of Chemical Science of the University of Science and Technology of China and Professor Zhang Huafeng's group from the School of Life Sciences discovered a new "smart" method to overcome the multidrug resistance of mouse tumors. We have proven its outstanding performance. Anti-multidrug resistance. The internationally renowned academic journal "German Applied Chemistry" recently published its findings online. Tumor multidrug resistance means that tumor cells are not only resistant to a specific chemotherapy drug due to long-term exposure to this chemotherapy drug, but also cross-resistant to other chemotherapy drugs with different structures and functions. Refers to the phenomenon that may occur.

　　The phenomenon of multidrug resistance is due to the increased expression of multidrug resistance protein in the cell membrane. It has the ability to release, block or release it before reaching its intracellular target. The traditional method to solve this problem is to prevent the pumping effect of multidrug resistance or use nanocarriers to load large amounts of drugs, which will bring harmful and toxic substances to the organism. often. Therefore, it is very important to develop safer anti-multidrug resistance drugs. Different from the above method, the "smart" small molecule drug (2-cyanobenzothiazole-paclitaxel) designed by Liang Gaolin's research team is a fluin enzyme that is highly expressed in the cells after entering cancer cells. It can be assembled by itself under action. Nanoparticles containing paclitaxel are produced and concentrated in cancer cells. Nanomedicine slowly releases free paclitaxel through the action of cancer cell esterase to kill cancer cells. versus

　　Zhang Huafeng’s research team cooperated, we established a multidrug resistance model of cancer cells, and conducted experiments on tumor mice with 2-cyanobenzothiazole compared with existing paclitaxel. Paclitaxel was found to be drug resistant. In cancer cells and model tumor mice, the drug index increased by 4.5 times and 1.5 times, respectively, and did not cause toxicity in mice. Liang Gaolin said that this new anti-multidrug resistance strategy provides new ideas for safer drug design and cancer treatment, and has great potential in the clinical treatment of cancer.